Inhalon Biopharma
Clinical-stage biotechnology company developing inhaled monoclonal antibody therapies for acute respiratory infections. The organization advances a platform that delivers antibodies directly to the airways via handheld nebulizers and engineers antibody properties to trap pathogens in airway mucus, with programs in RSV, SARS-CoV-2, hMPV and influenza supported by preclinical animal models and early human clinical studies.
Industries
Nr. of Employees
small (1-50)
Inhalon Biopharma
Products
Inhaled muco‑trapping monoclonal antibody candidate for RSV (clinical-stage)
A nebulized antibody therapeutic engineered to trap RSV in airway mucus and promote clearance; advanced through IND-enabling studies and clinical evaluation.
Inhaled antibody candidates targeting SARS‑CoV‑2 (clinical and preclinical programs)
A portfolio of inhaled therapeutic approaches for SARS viruses, including muco‑trapping antibodies and an ACE2‑based decoy designed for aerosol delivery and broad variant potency.
Inhaled monoclonal antibody candidate for human metapneumovirus (hMPV)
Program to develop an inhaled antibody therapy for hMPV delivered via nebulization for direct airway clearance.
Inhaled Antibody Treatments
Inhalon is developing inhaled antibody treatments designed to provide immediate intervention, be self-administered, and work for all age groups. The treatment involves inhaling an antibody mist generated by a handheld vibrating nebulizer from third parties, which aerosolizes the antibody drug without changing its properties.
IN-006
An inhaled antibody treatment for COVID-19 that demonstrates stable nebulization and muco-trapping properties, supporting its development as a potent, dose-saving inhaled therapy.
IN-007
An inhaled ACE2-targeting therapeutic in development for SARS-CoV-2.
Inhaled muco‑trapping monoclonal antibody candidate for RSV (clinical-stage)
A nebulized antibody therapeutic engineered to trap RSV in airway mucus and promote clearance; advanced through IND-enabling studies and clinical evaluation.
Inhaled antibody candidates targeting SARS‑CoV‑2 (clinical and preclinical programs)
A portfolio of inhaled therapeutic approaches for SARS viruses, including muco‑trapping antibodies and an ACE2‑based decoy designed for aerosol delivery and broad variant potency.
Inhaled monoclonal antibody candidate for human metapneumovirus (hMPV)
Program to develop an inhaled antibody therapy for hMPV delivered via nebulization for direct airway clearance.
Inhaled Antibody Treatments
Inhalon is developing inhaled antibody treatments designed to provide immediate intervention, be self-administered, and work for all age groups. The treatment involves inhaling an antibody mist generated by a handheld vibrating nebulizer from third parties, which aerosolizes the antibody drug without changing its properties.
IN-006
An inhaled antibody treatment for COVID-19 that demonstrates stable nebulization and muco-trapping properties, supporting its development as a potent, dose-saving inhaled therapy.
IN-007
An inhaled ACE2-targeting therapeutic in development for SARS-CoV-2.
Services
Collaborative development and licensing partnerships to advance nebulized antibody candidates and related technologies; examples include co-development of nebulized formulations with external biopharma partners.
Aerosol characterization and stability evaluation of antibody therapeutics for compatibility with handheld nebulizers.
Collaborative development and licensing partnerships to advance nebulized antibody candidates and related technologies; examples include co-development of nebulized formulations with external biopharma partners.
Aerosol characterization and stability evaluation of antibody therapeutics for compatibility with handheld nebulizers.
Expertise Areas
- Inhaled biologic delivery
- Therapeutic antibody engineering (muco-trapping)
- Preclinical efficacy and translational models
- Clinical trial design and respiratory PK
Key Technologies
- Handheld nebulizer aerosol delivery
- Muco‑trapping monoclonal antibodies
- Antibody glycoengineering
- Animal respiratory challenge models (neonatal lamb, hamster)
News & Updates
Company presentation of clinical progress and preclinical data for inhaled antibody platform at ATS RIS 2026.
Poster presentation reporting aerosolization and stability data for an ACE2‑based decoy antibody using a vibrating mesh nebulizer.
Oral and poster presentations summarizing preclinical and clinical development supporting an inhaled RSV antibody candidate.
Peer‑reviewed publication reporting safety, tolerability, and respiratory/serum concentrations from a randomized Phase 1 study of a nebulized antibody.
Initial results from a Phase 1b human study demonstrating higher respiratory tract antibody concentrations with inhaled dosing compared with intravenous dosing.
Preclinical efficacy papers published in Advanced Science and Bioengineering & Translational Medicine demonstrating inhaled antibody benefits in animal models.
Company presentation of clinical progress and preclinical data for inhaled antibody platform at ATS RIS 2026.
Poster presentation reporting aerosolization and stability data for an ACE2‑based decoy antibody using a vibrating mesh nebulizer.
Oral and poster presentations summarizing preclinical and clinical development supporting an inhaled RSV antibody candidate.
Peer‑reviewed publication reporting safety, tolerability, and respiratory/serum concentrations from a randomized Phase 1 study of a nebulized antibody.
Initial results from a Phase 1b human study demonstrating higher respiratory tract antibody concentrations with inhaled dosing compared with intravenous dosing.
Preclinical efficacy papers published in Advanced Science and Bioengineering & Translational Medicine demonstrating inhaled antibody benefits in animal models.